CAR-T Clinical Trials in China 2026: How to Enroll, Top Hospitals & What Patients Need to Know

Updated May 2026 | 15 min read | Cancer Treatment

China is running more CAR-T cell therapy clinical trials than any other country on earth — over 500 registered studies as of 2026. For patients with leukemia, lymphoma, or myeloma who have exhausted standard treatments, clinical trial participation in China may offer access to next-generation CAR-T constructs not available anywhere else. This guide covers how to find recruiting trials, what eligibility looks like, the real costs, and how to enroll as an international patient.

Why China Leads CAR-T Clinical Trial Volume

China's CAR-T clinical trial boom started around 2017 and accelerated rapidly. By January 2024, China had registered 337 CAR-T trials focused on blood cancers and 111 targeting solid tumors — more than the United States in total trial count. The country's regulatory fast-track for cell therapies, large patient population, and government investment in biotechnology clusters created near-perfect conditions for rapid trial expansion.

As of 2026, seven CAR-T products have received NMPA (National Medical Products Administration) approval in China — the highest number of any country. But approved products represent only a fraction of the experimental constructs in active trials. Patients who enroll in trials gain access to these investigational products, sometimes at a fraction of the cost of commercial CAR-T therapy.

                Key fact: The United States has roughly 200 active CAR-T trials. China has over 500. Many of China's trials accept international patients directly, with dedicated coordinators and English-speaking staff in major hospital international departments.
            

Clinical Trials vs. Approved CAR-T Therapy: What's the Difference?

If you've been researching CAR-T therapy, you've likely seen two paths: approved therapies (Yescarta, Carvykti, Relma-cel, Fucaso, etc.) and clinical trials. Here's the practical difference:

Factor	Approved CAR-T Therapy	Clinical Trial Participation
Regulatory status	Fully approved by NMPA (China), FDA (US), EMA (EU)	Investigational — not yet approved, under study
Product consistency	Manufactured to exact commercial specifications	May vary by trial cohort; some trials test multiple constructs
Cost to patient	$80,000–$151,000 in China (commercial)	$0 to $80,000 depending on trial (some cover all costs)
Known safety data	Extensive — years of follow-up data available	Limited — shorter follow-up, some unknown long-term effects
Availability	Immediately available at participating hospitals	Subject to enrollment capacity and eligibility screening
Next-generation access	Limited to approved products	Dual-target, universal, and in-vivo CAR-T constructs available

For many patients, the choice comes down to whether they prefer the predictability of an approved product with known outcomes, or the potential upside of an experimental construct that may be more effective — with correspondingly unknown risks.

Cancers Treated in China's CAR-T Clinical Trials

Hematologic (Blood) Cancers

The majority of CAR-T trials in China target blood cancers, where the therapy has shown the strongest results:

Acute lymphoblastic leukemia (ALL) — particularly B-cell ALL in adults and children
Diffuse large B-cell lymphoma (DLBCL) — the most common type of non-Hodgkin lymphoma
Mantle cell lymphoma (MCL) — a rare, aggressive B-cell lymphoma
Multiple myeloma — cancer of plasma cells in the bone marrow
Chronic lymphocytic leukemia (CLL) — the most common leukemia in adults
Follicular lymphoma — slow-growing non-Hodgkin lymphoma
T-cell lymphomas — trials targeting T-cell malignancies using CD7, CD5 targets

Solid Tumors (Emerging Area)

CAR-T therapy has historically struggled with solid tumors due to the immunosuppressive tumor microenvironment. China's trials are at the frontier of solving this challenge:

Gastric cancer — trials targeting CLDN18.2, a protein highly expressed in gastric cancer cells
Pancreatic cancer — mesothelin (MSLN) targeted CAR-T trials
Lung cancer — EGFR-targeted and Nectin-4 targeted trials
Liver cancer — GPC3-targeted CAR-T for hepatocellular carcinoma
Colorectal cancer — trials targeting GUCY2C and other surface antigens

Solid Tumor Trials: What to Know

CAR-T for solid tumors is genuinely experimental. Response rates are lower than for blood cancers, and the biological challenges are substantial. If you are considering a solid tumor trial, ask the research team specifically about their published interim data — how many patients have been treated, and what percentage showed tumor shrinkage. A responsible team will share this data openly.

Top Hospitals Running CAR-T Clinical Trials in China

These hospitals have established track records, English-speaking coordinators for international patients, and active recruiting trials across multiple cancer types:

Shanghai Changhai Hospital (第二军医大学附属长海医院)

One of China's most prolific CAR-T research centers. Dr. Zhao Defeng has overseen more than 1,000 CAR-T patient treatments and has 23 active clinical trials. Changhai's hematology department runs trials across leukemia, lymphoma, and myeloma, and has an international patient office with English-speaking staff.

Leukemia Lymphoma Multiple Myeloma 23 Active Trials

Peking University People's Hospital (北京大学人民医院)

A leading center for CAR-T therapy in Northern China. The hospital's hematology institute has published extensively on CAR-T treatment outcomes and operates trials for DLBCL, ALL, and multiple myeloma. International patients can coordinate through the hospital's international medical center.

DLBCL ALL Myeloma

Ruijin Hospital, Shanghai Jiao Tong University (瑞金医院)

Ruijin has been at the center of China's CAR-T development since the early trials. The hospital's CAR-T program has produced several NMPA-approved products and continues to run investigator-initiated trials (IITs) for next-generation constructs. Well-established international patient pathway.

Lymphoma Leukemia CAR-T Manufacturing

Guangzhou Nanfang Hospital (南方医科大学南方医院)

A major CAR-T trial center in Southern China, particularly active in T-cell lymphoma trials and solid tumor CAR-T research. The hospital's hematology department runs investigator-initiated trials and has published peer-reviewed outcomes data that international patients can review.

T-Cell Lymphoma Solid Tumors CAR-T for Gastric Cancer

Zhejiang University School of Medicine Affiliated第一医院 (ZJU First Hospital)

Known for CAR-T trials targeting CD19 and BCMA, with active enrollment for B-cell malignancies and multiple myeloma. The hospital's translational research center works closely with the international patient team to coordinate screening and enrollment logistics.

BCMA CAR-T Multiple Myeloma CD19

Types of CAR-T Clinical Trials

Not all CAR-T trials are the same. Understanding the trial phases and constructs helps you evaluate which trials may be right for your situation:

Trial Phases

Phase	Purpose	Patient Population	Risk Level
Phase I	Safety and dosing — is this construct safe at different doses?	Small group, usually 10-30 patients	Highest uncertainty; primary goal is finding safe dose
Phase I/II	Safety + preliminary efficacy — does it work, and at what dose?	20-100 patients typically	Still significant uncertainty; early signal of whether it works
Phase II	Efficacy and side effects — does the treatment work well enough to proceed?	100-300 patients typically	Better characterized safety profile; efficacy signal more reliable
Phase III	Comparative effectiveness — is it better than standard treatment?	300-3,000+ patients	Closest to approved therapy; usually vs. control group

CAR-T Construct Types in Active Trials

CD19-targeted CAR-T — the most established target, used in B-cell blood cancers. Targets the CD19 protein found on most B-cell cancer cells.
BCMA-targeted CAR-T — used in multiple myeloma. Targets B-cell maturation antigen on plasma cells.
Dual-target CAR-T — targets two antigens simultaneously (e.g., CD19 + CD22) to reduce antigen escape, where cancer cells downregulate one target to evade therapy.
Allogeneic (Universal) CAR-T — uses engineered donor T-cells instead of the patient's own cells. Allows off-the-shelf treatment without the 2-3 week manufacturing wait.
In-vivo CAR-T — a newer approach where CAR genes are delivered directly into the patient's body (via viral vector) rather than manufacturing cells in a lab. Early-stage trials only.
Armored CAR-T — engineered to resist the immunosuppressive tumor microenvironment, particularly relevant for solid tumor trials.

Eligibility: Who Can Join a CAR-T Clinical Trial?

Each trial has specific eligibility criteria. Generally, trials look for patients who:

Have a confirmed diagnosis of a cancer type targeted by the trial
Have already received and progressed through standard treatment (most trials require this)
Meet minimum and maximum age requirements (varies by trial)
Have adequate organ function (heart, liver, kidneys must be functioning well enough to tolerate treatment)
Have measurable disease — tumors that can be tracked and evaluated
Are not currently on immunosuppressive medications
Have no active infections or other serious medical conditions

                Common reasons patients are excluded: prior CAR-T therapy targeting the same antigen, significant cardiac disease, active infections (including HIV or hepatitis B/C), CNS involvement from cancer, or recent major surgery. Exclusion criteria exist because the treatment can be physically demanding and may interact with other conditions.
            

What to Prepare for Eligibility Screening

Before enrolling, hospitals will request:

Complete medical records in English or Chinese (including prior treatments, scans, and pathology reports)
CT, PET-CT, or MRI imaging showing current disease status
Bone marrow biopsy results (for leukemia and myeloma patients)
Blood test results showing organ function
Confirmation of prior treatment history — most trials require documented failure of at least 2 prior lines of therapy

Real Costs for International Patients

One of the main advantages of joining a CAR-T trial in China is cost. Clinical trial costs vary significantly depending on the trial type and whether the sponsor covers treatment expenses:

Cost Category	Typical Range	Notes
Trial participation fee	$0 – $80,000	Some sponsor-funded trials cover all costs; others charge for the investigational product
Leukapheresis (T-cell collection)	$5,000 – $15,000	If not covered by trial sponsor; often included
Hospital stay (14-30 days)	$3,000 – $12,000	CAR-T requires inpatient monitoring; CRS management may extend stay
Fludarabine/cyclophosphamide conditioning	$1,000 – $5,000	Lymphodepletion chemotherapy given before CAR-T infusion
ICU backup (if needed)	$1,000 – $5,000/day	Severe CRS management; many patients do not need ICU
Travel and accommodation	$3,000 – $10,000	Varies by origin country and duration of stay
Total estimated range	$15,000 – $120,000	Versus $400,000-$600,000 for commercial CAR-T in the US

Commercial CAR-T therapy in the United States costs $500,000–$699,000 for the treatment alone, before hospital fees. Even with travel, accommodation, and trial fees, participating in a Chinese CAR-T trial typically costs 70-90% less than receiving commercial CAR-T in the US.

The Enrollment Process: Step by Step

Step 1 — Research and Identify Trials (1-2 weeks)

Search ClinicalTrials.gov or the Chinese Clinical Trial Registry (ChiCTR) for recruiting CAR-T trials matching your cancer type. Hospitals like Changhai and Ruijin also list trials directly on their websites. International medical tourism agencies that specialize in CAR-T can also match you to appropriate trials.

Step 2 — Submit Medical Records (1 week)

Send complete medical records to the hospital's international patient office or your coordinating agency. Key documents: pathology reports, prior treatment history, recent CT/PET scans, bone marrow results, and blood work. The hospital's multidisciplinary team reviews whether you meet basic eligibility criteria.

Step 3 — Eligibility Confirmation (1-2 weeks)

The trial's principal investigator (PI) reviews your records and determines whether you qualify. Some trials require additional tests — a fresh biopsy, updated scans, or specific blood work that may not be in your records. The hospital will communicate any additional requirements.

Step 4 — Travel to China (1 day)

Once confirmed, you receive an official trial enrollment letter and appointment date. You'll need a medical visa (M visa or S1 visa depending on duration). The hospital's international office can provide the invitation letter required for the visa application.

Step 5 — In-Person Screening and Consent (3-5 days)

Upon arrival, you undergo final physical screening to confirm you're still fit for the trial. The research team explains the trial in detail, including known risks, unknown risks, your rights as a participant, and what happens if you withdraw. You sign informed consent before any trial procedures begin.

Step 6 — T-Cell Collection and Manufacturing (2-3 weeks)

If the trial uses autologous CAR-T (your own cells), you undergo leukapheresis — a blood draw that separates and collects T-cells. The cells are sent to a GMP manufacturing facility where they are engineered to express the CAR. Manufacturing takes 10-21 days. Some trials provide bridging therapy (temporary treatment) during this period to keep the cancer controlled.

Step 7 — Lymphodepletion Chemotherapy (3-5 days)

Before the CAR-T infusion, you receive conditioning chemotherapy (usually fludarabine + cyclophosphamide) to suppress your immune system so the engineered T-cells can expand more effectively after infusion.

Step 8 — CAR-T Infusion and Monitoring (14-30 days inpatient)

The CAR-T cells are infused into your bloodstream (similar to a blood transfusion). You are monitored in the hospital for cytokine release syndrome (CRS) and neurotoxicity — the two main acute side effects. Most patients develop fever and flu-like symptoms within the first week. The medical team manages this with tocilizumab and steroids when needed. You typically stay inpatient for 2-4 weeks.

Step 9 — Follow-Up (months to years)

After discharge, you need regular follow-up to assess treatment response (CT/PET scans, blood work) and monitor for delayed side effects. Some patients fly home and send follow-up results to the Chinese hospital remotely. Others stay in China or a nearby country for the first few months of monitoring. Most trials require follow-up for 1-2 years minimum.

Managing Expectations: Response Rates and Risks

What the data shows for blood cancers

CAR-T therapy has fundamentally changed outcomes for patients with relapsed/refractory blood cancers. For DLBCL, approximately 50-60% of patients achieve a complete response (no detectable cancer), and many of these responses are durable — meaning the cancer does not return. For ALL, pediatric and young adult patients have seen remission rates above 80% in some trials.

For multiple myeloma, BCMA-targeted CAR-T trials have shown overall response rates of 70-95%, with many patients achieving complete remission. China's trials have produced some of the strongest multiple myeloma data globally.

Understanding cytokine release syndrome (CRS)

CRS is the most common side effect of CAR-T therapy. When the engineered T-cells activate and multiply, they release inflammatory signaling molecules (cytokines) that can cause fever, low blood pressure, rapid heartbeat, and in severe cases, organ dysfunction. Nearly all patients experience some degree of CRS.

Grades of CRS:

Grade 1 — Fever (38°C/100.4°F or higher), mild flu-like symptoms. Managed with antipyretics.
Grade 2 — Fever plus low blood pressure requiring IV fluids, or oxygen levels dropping. Often managed with tocilizumab (an IL-6 receptor blocker).
Grade 3 — More severe hypotension requiring vasopressor support, or oxygen supplementation. Managed in ICU with steroids and tocilizumab.
Grade 4 — Life-threatening complications: multi-organ dysfunction, requires mechanical ventilation.

In experienced CAR-T centers, Grade 3-4 CRS occurs in approximately 10-20% of patients. Most centers now have extensive experience managing CRS, and mortality from CRS itself is rare at major Chinese CAR-T hospitals.

Neurotoxicity (ICANS)

Immune effector cell-associated neurotoxicity syndrome (ICANS) can cause confusion, aphasia (trouble speaking), seizures, and in severe cases, coma. Like CRS, it is manageable with steroids and supportive care when recognized early. Incidence varies by CAR-T product and disease type — B-cell ALL trials tend to see higher neurotoxicity rates than lymphoma trials.

What to Ask Before Enrolling in Any Trial

Before committing to any clinical trial, get answers to these questions directly from the principal investigator or study coordinator:

How many patients have been treated with this specific CAR-T construct? What percentage achieved a complete or partial response?
What is the CRS rate by grade? How many patients required ICU-level care?
Is this trial sponsor-funded (free to patient) or does the patient pay for the investigational product?
Does the trial cover management of side effects, including ICU costs if needed?
What happens if the treatment does not work — can the patient receive commercial CAR-T or another treatment?
Is long-term follow-up data published? Can I see the peer-reviewed results?
Does the hospital assist with medical visa applications and travel logistics?
What is the total expected cost, itemized, including all possible scenarios (extended ICU stay, additional treatments)?

"I had three rounds of chemo and two relapses before my doctor suggested CAR-T. In the US, the cost was quoted at $680,000 for Yescarta — completely out of reach. The trial in Shanghai cost a fraction of that, and I'm now 14 months in complete remission. The process was not simple, and the first week after infusion was rough. But I am here, and the cancer is gone." — Michael T., 47, DLBCL patient, treated at Shanghai Changhai Hospital, 2025

CAR-T Trials vs. Standard Care: Making the Decision

This decision involves weighing multiple factors — your cancer type, prior treatment history, financial situation, and risk tolerance. Here is a practical framework:

If your cancer is in complete remission on standard therapy: stay on standard therapy. CAR-T is most effective when used for active disease, and trial participation introduces unnecessary risk.
If your cancer has relapsed after 2+ treatments and you can access commercial CAR-T: compare the cost and data of commercial vs. trial CAR-T for your specific cancer type.
If commercial CAR-T is unaffordable ($400,000+ is typical in the US/Europe): a Chinese trial may be the most practical path to accessing the same technology at a fraction of the cost.
If you are interested in next-generation constructs (dual-target, universal, armored CAR-T): trials are the only access point. Discuss whether your cancer type has an appropriate next-generation trial with promising early data.

Frequently Asked Questions

How many CAR-T clinical trials does China have running in 2026?

China has more than 500 registered CAR-T clinical trials as of 2026, making it the country with the highest trial volume globally. Approximately 337 focus on blood cancers (leukemia, lymphoma, myeloma) and 111 on solid tumors. Dozens are actively recruiting international patients.

Can international patients join CAR-T clinical trials in China?

Yes. Many Chinese hospitals running CAR-T trials actively accept international patients, particularly at top-tier institutions in Shanghai, Beijing, and Guangzhou that have established international patient departments. Some trials cover treatment costs entirely; others charge $30,000-$80,000 for participation.

What is the difference between CAR-T clinical trial participation and approved CAR-T therapy?

Approved CAR-T therapies (like Yescarta, Carvykti) have completed trials and received regulatory approval — they are commercially available. Clinical trial participation gives access to experimental CAR-T products not yet approved, including next-generation constructs (dual-target, universal, in-vivo) that may be more effective but carry unknown risks.

What are the main risks of joining a CAR-T clinical trial in China?

The main risks are cytokine release syndrome (CRS) and neurotoxicity — common to all CAR-T therapies. In trials, additional risks include: the experimental construct may not work as expected, long-term follow-up data is limited, and some trial costs may not be covered by your home country's insurance. Treatment is typically provided at a hospital with ICU backup.

What cancers are eligible for CAR-T clinical trials in China?

The majority of recruiting trials target B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, multiple myeloma, and chronic lymphocytic leukemia. A growing number of trials also target solid tumors including gastric cancer, pancreatic cancer, and lung cancer.

How long does the CAR-T clinical trial process take from start to treatment?

The full process — from initial medical record submission to CAR-T infusion — typically takes 4-8 weeks. Medical record review and eligibility confirmation takes 2-3 weeks. T-cell collection and manufacturing takes 2-3 weeks. Some trials can accelerate this for urgent cases, but rushing the manufacturing process can compromise cell quality.

Will my home country's insurance cover CAR-T clinical trial costs in China?

Most likely not. International health insurance typically does not cover treatment received outside your coverage area, and clinical trial participation is almost never covered. Some travel insurance policies cover emergency medical evacuation. Check with your insurer before committing to a trial, and budget for the full cost yourself.

Need Help Finding the Right CAR-T Trial?

Our coordinators have direct contacts at Shanghai Changhai, Ruijin, Peking University People's, and other leading CAR-T centers. Send us your medical summary and we will match you to trials you may qualify for — with full cost transparency before you travel.

Free case review. Response within 48 hours.

Request Trial Matching Service

Sources

CancerFax, "CAR T Cell Therapy in China: Patient Guide," April 28, 2026 — cancerfax.com
China Clinical Trial Registry (ChiCTR), CAR-T trial registration data, 2026
ClinicalTrials.gov, CAR-T cell therapy trials in China, search conducted May 2026
ChinMedAccess, "CAR-T Cell Therapy in China 2026: The World's Most Accessible Destination," March 26, 2026
National Medical Products Administration (NMPA), approved CAR-T products list, updated 2026
Zhao D. et al., CAR-T cell therapy outcomes in relapsed/refractory DLBCL — Shanghai Changhai Hospital published data, 2024-2025
GlobalData, CAR-T Clinical Trials Intelligence, China segment, Q1 2026